HARVARD BIOSCIENCE INC 8-K

What Happened Harvard Bioscience, Inc. announced that its stockholders approved a reverse stock split and an adjournment proposal at a Special Meeting held March 6, 2026. A total of 27,715,066 shares (≈61.97% of outstanding as of the Jan. 21, 2026 record date) were represented. The Board subsequently approved a final reverse split ratio of 1-for-10 and filed a Certificate of Amendment to the company’s charter to effect the split, with an effective time of 4:30 p.m. Eastern on March 13, 2026. Trading on the Nasdaq Global Market is expected to continue under the symbol “HBIO” on a split‑adjusted basis beginning March 16, 2026.

Key Details

• Shareholder vote totals for the Reverse Stock Split Proposal: 27,004,721 FOR, 677,700 AGAINST, 32,645 ABSTAINED.
• Adjournment Proposal vote totals: 26,970,042 FOR, 630,369 AGAINST, 114,655 ABSTAINED.
• The reverse split will combine every 10 shares into 1 share, reducing outstanding shares from approximately 44,179,894 to approximately 4,471,989.
• No fractional shares will be issued; the transfer agent will aggregate fractional interests, sell them in the open market, and pay cash (without interest) to holders entitled to fractional shares. New CUSIP: 416906204.

Why It Matters The reverse stock split will materially reduce the company’s outstanding share count and will be reflected in share price and per‑share metrics on a split‑adjusted basis once trading resumes March 16, 2026. Investors should note the effective date and new CUSIP for trading and settlement purposes, and that fractional-share holders will receive cash payments rather than fractional shares. This is a structural corporate action (not a change in the company’s total equity value) that can affect liquidity, per‑share figures, and how shares trade in the short term.